The SURPASS program (for type 2 diabetes) and SURMOUNT program (for obesity) together enrolled over 20,000 participants across multiple Phase III trials
Longer term For longer or repeated protocols, review trends every 3 months with a clinician
The BPC-157 peptide is documented in peer-reviewed literature as acting through at least two distinct, non-redundant molecular pathways simultaneously which may explain its unusually broad tissue-repair activity profile
You should not use the information provided herein to diagnose, prevent, or cure a health problem
Manufactured under strict quality standards, our peptide formulations are tested for purity, consistency, and reliability, providing researchers and healthcare professionals with trusted solutions for scientific exploration